The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to < 18 years of age).
Age: 6 - 17 years
Gender: All
We've found 2 total result s for "Migraine Disorders".
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Age: 6 - 17 years
Gender: All